Benefits of osimertinib treat a lung adenocarcinoma patient with germline EGFR T790M, somatic EGFR 19-Del, TP53 and PIK3CA mutations.

These observations suggest that germline mutations in EGFR T790M could be strongly linked to a familial predisposition to lung cancer.